# Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

Source: https://onco.cc/trials/nct06062810/  
OnCo record `nct06062810` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Raloxifene in advanced solid tumours, run by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, active and no longer recruiting.

## Summary

Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms is a phase 2/3 interventional study registered as NCT06062810 by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, with 600 participants enrolled, started 2025-06-21 and due to reach its primary completion in 2026-12-18. Interventions recorded: Raloxifene - Usual and Raloxifene - Study.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06062810
- Phase: 2/3
- Setting: Explore the Relationship Between Single Nucleotide Polymorphisms and Raloxifene Response and Toxicity in Patients With Breast Cancer LCIS
- Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- Enrolled: 600

## Sources

- ClinicalTrials.gov NCT06062810: https://clinicaltrials.gov/study/NCT06062810

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Raloxifene](https://onco.cc/drugs/raloxifene/)

---
JSON: https://onco.cc/api/v1/entities/nct06062810.json